Latest Breaking News On - Theseus pharmaceuticals - Page 3 : comparemela.com

Critical Analysis: Theseus Pharmaceuticals (NASDAQ:THRX) vs MoonLake Immunotherapeutics (NASDAQ:MLTX)

Critical Analysis: Theseus Pharmaceuticals (NASDAQ:THRX) vs MoonLake Immunotherapeutics (NASDAQ:MLTX)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesMoonlake immunotherapeuticMoonlake immunotherapeuticsTheseus pharmaceuticalsNews ratings for theseus pharmaceuticals dailyTheseus pharmaceuticals incGet free reportGiven theseus pharmaceuticalTheseus pharmaceuticals daily

Concentra Biosciences to Acquire Theseus Pharmaceuticals for $3 90 to $4 05/Shr

By Dean Seal Theseus Pharmaceuticals has agreed to be acquired by Concentra Biosciences for $3.90 to $4.05 a share in cash. The clinical-stage.

Concentra biosciencesTheseus pharmaceuticalsDean sealArticle normalBiotechnology servicesHealthcare life sciencesOwnership changesAcquisitions mergers shareholdingsAcquisitions mergersCorporate actionsCorporate industrial newsContent typesFactiva filtersC amp ampe industry news filterIndustrial newsLife sciences

Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3 90 and $4 05 in Cash per Share Plus a Contingent Value Right

CAMBRIDGE, Mass., Dec. 22, 2023 /PRNewswire/ Theseus Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery,.

United kingdomUnited statesTheseus pharmaceuticalsConcentra biosciencesDunn crutcherTheseus pharmaceuticals incPrnewswire theseus pharmaceuticals incGoodwin procterExchange commissionBase priceContingent value rights agreementTheseu boardTang capital partnersMerger agreementPrivate securities litigation reform actRecommendation statement

THRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Theseus Pharmaceuticals, Inc Is Fair to Shareholders -December 22, 2023 at 08:25 am EST

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Theseus Pharmaceuticals, Inc. to Concentra Biosciences, LLC for between $3.90 and $4.05 in cash is fair to Theseus.

Halper sadehZachary halperConcentra biosciencesTheseus pharmaceuticals incTheseus pharmaceuticalsDaniel sadeh

Theseus Pharma To Acquire Concentra Biosciences For $4 05/Shr In Cash

Biopharmaceutical company Theseus Pharmaceuticals, Inc. (THRX) announced Friday it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC will acquire Theseus for a price per share of Theseus common stock of between $3.

Theseus pharmaceuticals incConcentra biosciencesTheseus pharmaceuticalsContingent value rightsMerger agreementConcentra biosciencesTheseus pharmaceuticalsIopharmaceutical company theseus